The tissue-selective oestrogen complex agent bazedoxifene and conjugated oestrogens may be a promising new treatment option for menopause, American doctors suggest.
Their review of published reports from phase III trials of the combination found it alleviated menopausal symptoms and prevented postmenopausal bone loss, had an overall good safety profile with an incidence of amenorrhea and breast pain similar to placebo and did not stimulate the endometrium.
Smaller studies documented improved hot flushes and vaginal atrophy but longer term safety regarding cardiovascular and breast effects has not been established.
Gend Med. 2011; 8 :57-68 Treating Menopausal Symptoms With a Tissue-Selective Estrogen Complex
Content updated 25 May 2011